ScreenerHero

ARCT Arcturus Therapeutics Holdings Inc.

NAS · US · Healthcare · Biotechnology · arcturusrx.com
12.77USD-1.81%Mkt Cap: 362.82M $P/E: —

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA techno…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap362.82M USD
Enterprise Value200.95M USD
Revenue (TTM)29.37M USD
Gross Profit-57.41M USD
Net Income (TTM)-65.78M USD
Revenue/Share1.05 USD
Last Price12.77 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees106
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.59
PEG—
EV/EBITDA-2.02
EV/Revenue6.84
P/S12.58
P/B2.15
EPS (TTM)-2.95
EPS (Forward)-3.62
52W Range
5.50039% of range24.17
52W High24.17 USD
52W Low5.500 USD
Profitability
Gross Margin-195.50%
Oper. Margin-863.30%
EBITDA Margin0.00%
Profit Margin-97.86%
ROE-30.74%
ROA-24.26%
Growth
Revenue Growth-89.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-74.27M USD
CapEx (TTM)230.00K USD
FCF Margin65.58%
FCF Yield5.31%
Net Debt-168.55M USD
Net Debt/EBITDA1.69
Balance Sheet
Debt/Equity0.12
Current Ratio5.88
Quick Ratio5.76
Book Value/Sh6.04 USD
Cash/Share6.74 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateNov 16, 2017
Splits
Last Split1:7
Split DateNov 16, 2017
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)23.20 USD
Upside (mean)+81.7%
Target Range9.000 USD – 41.00 USD
9.000+81.7% to mean41.00
# Analysts10
Ownership
Shares Out.28.42M
Float26.15M
Insiders7.99%
Institutions83.08%
Short Interest
Short Ratio3.7d
Short % Float23.93%
Short % Out.19.24%
Shares Short5.47M
Short (prev mo.)6.53M
Technical
SMA 5011.96 (+6.7%)
SMA 2008.536 (+49.5%)
Beta2.48
S&P 52W Chg16.45%
Avg Vol (30d)1.20M
Avg Vol (10d)868.39K
Technical Indicators
RSI (14)47.2
MACD0.3505
MACD Signal0.7636
MACD Hist.-0.4131
BB Upper16.18 USD
BB Middle14.25 USD
BB Lower12.33 USD
BB Width27.07%
ATR (14)1.264 USD
Vol Ratio (20d)0.64x